Innovative drug overseas authorization cooperation intensifies landing, Chinese pharmaceutical companies accelerate global layout.

Recently, domestic innovative pharmaceutical companies have seen a continuous increase in overseas business expansion cooperation, with companies such as Akeso, Frontage Bio and BeiGene all announcing major overseas licensing agreements. From small molecule nucleic acid drugs to tumor immunotherapy, from product authorization to platform cooperation, the domestic innovative pharmaceutical industry is deeply connecting with global pharmaceutical companies. Industry insiders believe that the intensive international collaborations not only bring ample cash flow and assist in research and development, but also signify that China's innovative pharmaceutical industry is transitioning from single-product licensing to technology output, platform building, and global collaboration, continuously realizing the globalization value of the core race track.